Active Ingredient History
Tiomolibdic acid is a chelating agent under investigation for the treatment of cancer and of Wilson's disease, a rare and potentially fatal disease in which the body cannot regulate copper. It is developed by Wilson Therapeutics and used in form of the salt bis-choline tetrathiomolybdate. Wikipedia
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Breast Neoplasms (Phase 2)
Carcinoma, Hepatocellular (Phase 2)
Carcinoma, Non-Small-Cell Lung (Phase 1)
Colorectal Neoplasms (Phase 2)
Esophageal Neoplasms (Phase 2)
Healthy Volunteers (Phase 1)
Hepatolenticular Degeneration (Phase 3)
Idiopathic Pulmonary Fibrosis (Phase 1/Phase 2)
Liver Cirrhosis, Biliary (Phase 3)
Lung Neoplasms (Phase 1)
Melanoma (Phase 2)
Multiple Myeloma (Phase 1/Phase 2)
Prostatic Neoplasms (Phase 2)
Psoriasis (Phase 2)
Triple Negative Breast Neoplasms (Phase 1/Phase 2)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue